Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The tortoise (Eli Lilly) has caught the hare (Novo Nordisk), according to a report from BMO Capital Markets, which cites the ...

OrderlyMeds fights back after Big Pharma crackdown, igniting a battle over the future of personalized medicine ...

Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, ...

To what extent will health clinics go to keep selling in-demand weight-loss drugs now that the FDA has outlawed cheaper ...

Lilly plans to submit orforglipron for approval in weight management by the end of 2025, with a type 2 diabetes application ...

The analyst highlights that Lilly’s drugs, Mounjaro and Zepbound, will likely keep gaining U.S. market share from Novo ...

U.S. pharma giant Eli Lilly And Co (NYSE:LLY) announced the launch of its popular weight loss drug Mounjaro (tirzepatide) in ...

A Lilly statement said, "We will continue to take action to stop these illegal actors and urgently call on regulators and law ...

Skye shares surge after new data shows nimacimab reduces weight over 30% with tirzepatide, with stable potency and promising ...

Eli Lilly's experimental pill worked as well as blockbuster drug Ozempic to lower weight and blood sugar in a trial of ...

Eli Lilly and Company’s LLY shares have lost 8.2% in the past month. A lot of this price decline is due to the global ...